Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -30.15M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 501
Avg Vol 5,710
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 69%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-f...

Phone: 484 254 6134
Address:
1201 Orange Street, Suite 600, Wilmington, United States
Latest News on NRXPW
NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript

Nov 17, 2025, 11:57 AM EST - 3 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript


NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

Aug 20, 2025, 12:23 PM EDT - 6 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript


NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

May 16, 2025, 8:46 PM EDT - 10 months ago

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript